Last reviewed · How we verify
ESB Thoracic
ESB Thoracic, marketed by George Washington University, holds a niche position in the thoracic medical space with its unique mechanism of action. The drug's key strength lies in its composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | ESB Thoracic |
|---|---|
| Sponsor | George Washington University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Thoracic Epidural Analgesia With Bilateral Erector Spinae Plane Block in Radical Cystectomy Surgery (NA)
- Erector Spinae Block for Thoracic Surgery (PHASE4)
- Ultrasound Guided Rhomboid Intercostal Subserratus Plane Block vs Erector Spinae Plane Block in Open Nephrectomy (NA)
- Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery (PHASE3)
- Continuous Erector Spinae Block Versus Continuous Paravertebral Block (PHASE3)
- Comparison of M-TAPA Block and ESP Block İn Laparoscopic Cholesystektomy (NA)
- Identification of Best Postoperative Analgesia Method Following a Minimally Invasive Repair of Pectus Excavatum (NA)
- TEA, ESB and Paravertebral Block During Single-lung Ventilation for Lung Resection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESB Thoracic CI brief — competitive landscape report
- ESB Thoracic updates RSS · CI watch RSS
- George Washington University portfolio CI